81424-67-1
81424-67-1
Chemical Structure
Caracemide
Synonym(s): NSC-253272
- CAS No.: 81424-67-1
- Formula:C6H11N3O4
- Molecular Weight:189.17
IUPAC Name: N-(methylcarbamoyl)-N-((methylcarbamoyl)oxy)acetamide
InChIKey: JURAJLFHWXNPHG-UHFFFAOYSA-N
SMILES: CC(N(OC(NC)=O)C(NC)=O)=O
Biological Activity: Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Caracemide | 95.0% | Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Slatter JG, et al. Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol. 1993 May-Jun;6(3):335-40. [Content Brief]
- [2]. Larsen IK, et al. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J Biol Chem. 1992 Jun 25;267(18):12627-31. [Content Brief]
